There is a 3-aa insertion in the transmembrane (TM) domain of the p68m protein-tyrosine kinase encoded by avian sarcoma virus UR2 v-ros as compared with that of the protooncogene c-ros. The effect of this insertion on biological function and biochemical properties of v-Ros protein was investigated by deleting these 3 aa to generate the mutant TM1. This mutant has greatly reduced transforming, mitogenic, and tumorigenic activities despite the fact that the protein- codes for a 68-kDa TM Gag-Ros fusion PTK with the Gag portion protruding extracellularly (12) . Both Gag and TM domains are essential for the transforming function of p689-ros (13, 14) .
tyrosine kinase activity and cell-surface localization of TMl protein are unaffected. However, unlike UR2 protein, mutant TM1 protein becomes glycosylated, is differentially phosphorylated, and fails to induce tyrosine phosphorylation ofa 88-kDa protein and a major substrate of insulin receptor, insulin receptor substrate 1. The TM1 protein is unable to associate with phosphatidylinositol 3-kinase and fails to promote association of insulin receptor substrate 1 with phosphatidylinositol 3-kinase. By contrast, tyrosine phosphorylation of Shc protein and phospholipase Cy as well as interaction of Grb2 protein with Shc and SOS protein signaling components are unaltered in the TM1 infected cells. Our results show that the TM-domain sequence of p68Pg profoundly affects its function and substrate interaction. The mutant derines a signaling pathway including phosphatidylinositol 3-kinase, insulin receptor substrate 1, and possibly an 88-kDa protein that does not overlap the Ras pathway and is important for full transforming and mitogenic potency of v-ros protein-tyrosine kinase.
codes for a 68-kDa TM Gag-Ros fusion PTK with the Gag portion protruding extracellularly (12) . Both Gag and TM domains are essential for the transforming function of p689-ros (13, 14) .
Our recent study (11) showed that the 3' change of v-ros has little effect on activation of the transforming potential of c-ros, whereas 5' truncation (deleting all but 6 aa upstream of the TM domain) and fusion to gag are required for activating c-ros transforming activity, although this activity is not as potent as that of v-ros. Combination of the 5' alteration and the 3-aa insertion in the TM domain is sufficient to convert c-ros into an oncogene as potent as v-ros (11) . This observation suggests that the 3-aa insertion in the TM domain of v-Ros may be important to its function.
To further inquire into the role of the 3-aa insertion of v-Ros, we deleted this sequence and investigated the transforming function and signal transduction of the mutant protein. Our results indicate that the 3-aa deletion has no effect on PTK activity of v-Ros, but this deletion does result in greatly reduced transforming and mitogenic potency, as well as altered protein modifications and substrate interaction despite the fact that the cytoplasmic domain of the mutant protein is unaltered. Thus, the mutant allows us to identify certain cellular proteins and a signaling pathway that may be important in cell transformation. This mutant also shows that specificity of the v-Ros PTK-substrate interaction is not solely determined by its cytoplasmic domain. Protooncogene c-ros codes for a receptor protein-tyrosine kinase (PTK) (1) with sequence and structural hierarchy closely resembling those of the sevenless protein ofDrosophila (2) (3) (4) (5) . In addition, the PTK domain of Ros shares a greater homology with those of insulin receptor and insulin-like growth factor I receptor (IGFR) than any other PTK family members (3) (4) (5) (6) (7) . The ligand of c-Ros remains unknown; however, c-Ros is specifically expressed in the epithelial cells of kidney tubules and villi of intestine and has been suggested to operate in their development and mature function (3-5, 8, 9) . Spontaneous transduction of c-ros by an avian leukosis virus resulted in its structural alterations and oncogenic activation (10) . The oncogene v-ros carried in the genome of avian sarcoma virus UR2 differs from c-ros structurally in three aspects (11) : (i) all 1873 aa of the extracellular domain of c-Ros except the last 6 aa are truncated in v-Ros, and the remaining C-terminal c-Ros is joined at its N-terminus to retroviral Gag sequence to form an in-frame Gag-Ros fusion polypeptide, (ii) there is a 3-aa (Ser-Leu-Thr) insertion in the middle of the transmembrane (TM) domain of v-Ros in comparison with that of c-Ros, and (iii) there is a small C-terminal deletion and fusion of c-Ros to viral Env sequence to generate the C-terminal end of v-Ros. There are no mutations in v-Ros other than these three changes. v-ros MATERIALS AND METHODS Cells, Viruses, Biological Assays, and DNA Transfection. The preparation of chicken embryo fibroblasts (CEF) and colony assay of virus-infected CEF were as described (15) . Molecular clones and their derived viruses of UR2, UR2AV, CC5d (a c-ros-derived virus), VC (a v-ros x c-ros recombinant), SRCxROS (a src x ros recombinant), NM1 (encoding a Gag-IGFR fusion protein), and UfIGFR (encoding the full-length human IGFR) have been described (10, 11, 16, 17) . Transfection of DNA into CEF by the calcium phosphate or Polybrene method was as described (11, 14) .
Antibodies. Anti-phosphotyrosine (a-P-Tyr) antibodies (Abs) Py2O and RC20, anti-phospholipase Cy (PLCy), and anti-Grb2 were purchased from Transduction Laboratories (Lexington, KY). The polyclonal a-P-Tyr serum GApYl and the anti-Ros serum have been described (16 (11) (12) (13) (14) . In vitro PTK assay, PI3-kinase assay, immunoanalysis of tyrosinephosphorylated total or specific proteins, and biotin-labeling of surface proteins have been described (11) (12) (13) (14) 17) . Inhibition of glycosylation by tunicamycin treatment was done by described procedures (11) . For inhibition ofGolgi function by brefeldin A (20, 21) , CEF were incubated with the inhibitor (1 pg/ml) for 2 hr before [35S]methionine labeling; this incubation continued over a 4 hr-labeling period. Possible oligomerization of Ros proteins under nondenaturation condition in polyacrylamide gels and by glycerol gradient sedimentation was analyzed by described methods (11, 17, 22) . Tryptic and V8 protease peptide mappings of in vitro or metabolically labeled Ros proteins were done as reported (12, 23) .
RESULTS
Construction of TM1 Mutant. CC5d is a weak transforming virus containing the 5' truncated c-ros fused at its 5' end to gag at the position identical to that of UR2 gag-ros (11) . The only differences between p68Pa6W fusion proteins of UR2 and CC5d are the 3-aa insertion in the TM domain and the C-terminal change in UR2 protein. A BamHI-Mam I DNA fragment of 410 bp containing the TM domain was prepared from CC5d DNA and used to replace the corresponding region of UR2 DNA. The DNA fiagment was sequenced and confirmed as identical to that of UR2 except for absence of the 3-aa insertion. The resulting virus, TM1, is identical to UR2 virus except for the 3-aa absence in the TM domain ( Fig. 1) .
Transforming, Mitogenic, and Tumorigenic Activities of TM1 Mutant. TM1 and UR2 DNAs were individually transfected together with UR2AV DNA into CEF for comparison of their mitogenic and transforming activities. TM1 has a markedly reduced transforming activity, as judged by morphological alteration and colony-forming ability of the transfected CEF (Fig. 2 (Fig. 3B) . Like UR2 p68M-m°, TM1 protein is not dimerized, as reflected by unaltered gel mobility with or without denaturation by 2-mercaptoethanol (Fig. 3C ). Under the same conditions, the NM1 Gag-IGFR protein existed as a monomer after denaturation and as dimers without denaturation, even with iodoacetamide, which prevented artificial oligomerization during protein extraction, confirming our previous observation (17) . In addition, possible formation of protein complex was also investigated by glycerol gradient sedimentation of proteins extracted with Nonidet P-40 lysate buffer without denaturing agents. No evidence of protein complex formation was seen for either UR2 or TM1 p68g-r°s (data not shown).
During analysis, we noticed that the TM1 protein appeared heterogeneously as multiple bands (Fig. 3) . We suspected that this might reflect differential phosphorylation and/or glycosylation. Fig. 4A shows that the upper bands of TM1 proteins disappeared upon tunicamycin treatment, suggesting that glycosylation was most likely responsible for the observed heterogeneity. Brefeldin A, an inhibitor of protein transport to Golgi apparatus and further modification in this organelle (20, 21) also affected appearance ofthe TM1 protein but not of the UR2 protein (Fig. 4C) . Glycosylation of the TM1 protein was further supported by digestion with N-glycosidase F, which affected TM1 protein and IGFR but not the UR2 protein (Fig. 4B) . When CC5d and CV5d proteins, both lacking the 3-aa insertion in the TM domain, were examined, similar results with tunicamycin and brefeldin A were seen (data not shown). These data indicate that absence ofthe 3-aa insertion in the TM domain allows glycosylation of the TM1 protein. Conversely, the presence of such amino acids prevents glycosylation of UR2 protein.
We next examined ability of the TM1 protein to phosphorylate cellular substrates. Fig. SA shows that overall, the TM1 p6859-rOS is as efficient as that of UR2 in phosphorylating cellular proteins. However, a tyrosine-phosphorylated ( Tyr) 88-kDa protein is missing in the TM1-infected CEF; this was more clearly seen with the polyclonal a-P-Tyr serum GApYl (Fig. 5B) . A monoclonal Ab 5C2 (Fig. SC) , which we recently prepared against the P-Tyr proteins from UR2-transformed CEF, recognized an 88-kDa protein that was tyrosine-phosphorylated in the UR2-infected, but not in the TM1-infected, cells (Fig. 5C) , and this band comigrated with the 88-kDa protein band detected in the total protein immunoblot described above. The apparently stronger phosphorylation ofa 38-kDa protein in TM1 cells was not reproducible (compare Fig. 5 A and B) . f We reported (24) that the p68M1' could associate with P13-kinase; we compared this property in TM1 and UR2 proteins. Fig. 6A shows that TM1 protein failed to associate with P13-kinase. Because the PTK domain of v-Ros shares a high homology with that of insulin receptor and PL3-kinase can be activated by the major substrate of insulin receptor, IRS1 (25) , we examined the ability of TM1 protein to phosphorylate IRS1 and promote its association with P13-kinase. Fig. 6 shows that unlike in UR2-transformed CEF, IRS1 was not appreciably tyrosine-phosphorylated and associated with P13-kinase in the TM1-infected cells.
We also examined the interaction of the Ros proteins with other signaling components, including PLCy and those in the Ras pathway-such as Shc, Grb2, and SOS protein (26, 27) . Fig. 7 shows that the extent of tyrosine phosphorylation of Shc and PLCy was similar in TM1-and UR2-infected cells. In addition, immunoprecipitation of UR2-and TM1-infected cell lysates with anti-Shc or anti-Sos followed by immunoblotting with anti-Grb2 revealed indistinguishable interaction between Grb2 and Shc or Sos (data not shown). Similar immunoprecipitation with anti-Grb2 followed by immunoblotting with a-P-Tyr Ab RC20 also did not differ noticeably in Grb2-associated P-Tyr protein patterns between the two virus-infected cultures (data not shown).
Except for the difference in glycosylation, TM1 protein appears indistinguishable from UR2 protein in various aspects, including expression level, PTK activity, extent of autophosphorylation, status of protein complex, and cellsurface localization. To explore the basis for the observed differential substrate interaction of TM1 protein, we looked for a possible difference in its sites of phosphorylation. The UR2 and TM1 p68gag-r°s labeled with 32p metabolically or by in vitro kinase reaction were subjected to V8 protease or tryptic mapping. The V8 protease cleavage pattern of the in vitro autophosphorylated TM1 protein, labeled exclusively at tyrosine sites, is identical to that of the UR2 protein, except that a small peptide fragment is missing among the cleavage products of TM1 protein (Fig. 8) The different effects of brefeldin A, which perturbs protein transport from endoplasmic reticulum to Golgi apparatus and subsequent modifications there (20, 21) , imply that posttranslational trafficking of TM1 and UR2 proteins may also differ. called CC5d and CV5d, respectively, all code for Gag-Ros fusion proteins without the 3-aa insertion in the TM domain, and they are all glycosylated (11) . Therefore, the insertion appears to perturb the Ros protein structure and thus prevent it from being recognized by glycosylating enzymes during the initial stages of protein translocation and modification in endoplasmic reticulum. There are numerous reports on the effect of mutations of amino acids surrounding TM domains TM1 UR2 TM1 UR2 (28) . However, to our knowledge, the observation that a small amino acid insertion in the middle of the TM domain causes differential glycosylation has not been previously reported. A single Val --Glu mutation in the TM domain of c-Neu, an epidermal growth factor receptor-related PTK, is responsible for its activation of cell transforming and tumorigenic potential (29) . The mutation apparently locks the Neu protein in a stable dimerized state, mimicking that of ligand binding, and activates PTK activity and autophosphorylation (30) (31) (32) . The mutation was also reported to increase the turnover rate of Neu protein and render it differentially phosphorylated at certain Thr/Ser residues and refractive to inhibition by protein kinase C (33, 34) . By contrast, two studies indicated that insulin receptor and epidermal growth factor receptor were relatively refractive to mutations within their TM domains, including the similar Val -3 Glu mutation (35, 36 (26, 27) . Because The mechanism for the observed differential substrate interaction is unclear. Insertion of 3 aa in the TM domain of UR2 p689-r may cause conformational change of the TM peptide spanning the membrane and alter interaction with certain membrane protein(s) which, in turn, affects conformation of the cytoplasmic domain, changing phosphorylation and substrate interaction. Alternatively, the insertion may cause protrusion of some amino acids into the cytoplasmic domain, directly affecting its configuration. It was reported that a point mutation in the domain of T-cell antigen receptor ,3 chain caused its failure to assemble with CD3 complex (37) .
Peculiarly, although the Gag-IGFR fusion protein forms dimers on cell surface, Gag-Ros does not (Fig. 3 and ref. 17) . In NM1-encoded Gag-IGFR, Gag is linked directly to the TM domain of IGFR (17) . In p68M-rS, Gag is linked to Ros at a position 6 aa upstream ofthe TM domain (10) . We suspect that the determinants for those fusion proteins exist either as dimers or as single polypeptides on the cell surface that probably reside in the TM and/or cytoplasmic domains. Both an earlier study (22) and our current study failed to detect dimerization of p68M8m. Although dimerization may be important for Gag-IGFR function, it appears unimportant for Gag-Ros. However, whether monomeric GagIGFR is functional remains to be seen. Study of chimeric recombinants between Gag-Ros and Gag-IGFR should resolve those questions.
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